| BR Advanced/Metastatic - abemaciclib | 1.0.0 | 24/07/2024 |
| BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3] | 1.0.0 | 01/09/2022 |
| BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 3/4] | 1.0.0 | 01/09/2022 |
| BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] and aTEZOLIzumab | 2.0.0 | 22/04/2022 |
| BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] | 1.0.0 | 24/03/2022 |
| BR Metastatic - capecitabine 1000 | 1.0.0 | 29/06/2021 |
| BR Metastatic - capecitabine 1000 and trastuzumab Q3W | 1.0.0 | 22/04/2022 |
| BR Metastatic - capecitabine 1000, trastuzumab and tucatinib | 1.0.0 | 16/08/2024 |
| BR Metastatic - capecitabine 1250 | 1.0.0 | 16/11/2021 |
| BR Metastatic - capecitabine 1500 [flat dosing] [7-days on 7-days off] | 1.0.0 | 24/07/2024 |
| BR Metastatic - capecitabine 750 and neratinib | 1.0.0 | 24/07/2024 |
| BR Metastatic - cARBOplatin | 2.0.0 | 22/04/2022 |
| BR Metastatic - cARBOplatin [2 AUC] and gemcitabine | 1.0.0 | 29/05/2024 |
| BR Metastatic - cARBOplatin [5 AUC] and gemcitabine | 3.0.0 | 30/05/2024 |
| BR Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] | 1.0.0 | 18/09/2023 |
| BR Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] | 1.0.0 | 18/09/2023 |
| BR Metastatic - CYCLOPHOSPHamide and metHOTREXATe [low dose oral] | 3.0.0 | 17/08/2023 |
| BR Metastatic - denosumab | 1.0.0 | 22/10/2021 |
| BR Metastatic - DOCEtaxel and trastuzumab Q3W | 1.0.0 | 22/04/2022 |
| BR Metastatic - DOCEtaxel Q3W | 1.0.0 | 22/04/2022 |
| BR Metastatic - DOCEtaxel, pERTUZumab and trastuzumab | 1.0.0 | 22/04/2022 |
| BR Metastatic - DOXOrubicin Q1W | 1.0.0 | 18/09/2023 |
| BR Metastatic - DOXOrubicin Q3W | 1.0.0 | 22/10/2021 |
| BR Metastatic - EC [epirubicin and CYCLOPHOSPHamide] | 1.0.0 | 22/10/2021 |
| BR Metastatic - Enhertu [trastuzumab deruxtecan] | 1.0.0 | 26/08/2024 |
| BR Metastatic - eribulin | 1.0.0 | 22/10/2021 |
| BR Metastatic - everolimus and exemestane | 1.0.0 | 22/10/2021 |
| BR Metastatic - fulvestrant | 1.0.0 | 22/10/2021 |
| BR Metastatic - gemcitabine | 1.0.0 | 22/10/2021 |
| BR Metastatic - goserelin Q12W | 1.0.0 | 22/10/2021 |
| BR Metastatic - goserelin Q4W | 1.0.0 | 22/10/2021 |
| BR Metastatic - Kadcyla [trastuzumab emtansine] | 1.0.0 | 22/10/2021 |
| BR Metastatic - MMM [mitomycin, mitoxantrone and metHOTREXATe] | 2.0.0 | 22/04/2022 |
| BR Metastatic - olaparib | 1.0.0 | 19/04/2023 |
| BR Metastatic - PACLItaxel Q1W | 2.0.0 | 22/04/2022 |
| BR Metastatic - PACLItaxel Q1W and trastuzumab Q3W | 1.0.0 | 22/10/2021 |
| BR Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W | 1.0.0 | 22/10/2021 |
| BR Metastatic - palbociclib | 1.0.0 | 22/10/2021 |
| BR Metastatic - pamidronate | 1.0.0 | 22/10/2021 |
| BR Metastatic - pembrolizumab Q3W [flat dosing] | 1.0.0 | 22/10/2021 |
| BR Metastatic - ribociclib | 1.0.0 | 29/05/2024 |
| BR Metastatic - sacituzumab govitecan | 1.0.0 | 16/08/2024 |
| BR Metastatic - trastuzumab Q3W | 1.0.0 | 22/10/2021 |
| BR Metastatic - trastuzumab Q3W and vinORELBine [IV] | 1.0.0 | 22/10/2021 |
| BR Metastatic - trastuzumab Q3W and vinORELBine [oral] | 1.0.0 | 18/09/2023 |
| BR Metastatic - trastuzumab subcutaneous | 1.0.0 | 22/10/2021 |
| BR Metastatic - vinORELBine [IV] | 1.0.0 | 22/10/2021 |
| BR Metastatic - vinORELBine [IV] Q1W | 1.0.0 | 22/10/2021 |
| BR Metastatic - vinORELBine [IV], pERTUZumab and trastuzumab Q3W | 1.0.0 | 01/09/2022 |
| BR Metastatic - vinORELBine [oral] | 1.0.0 | 01/09/2022 |
| BR Metastatic - vinORELBine [oral], pERTUZumab and trastuzumab Q3W | 1.0.0 | 26/08/2024 |
| BR Metastatic - zoledronic acid Q12W | 1.0.0 | 16/11/2021 |
| BR Metastatic - zoledronic acid Q4W | 1.0.0 | 16/11/2021 |
